Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Benjamin Levy is a thoracic medical oncologist and the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, as well as an assistant professor of oncology for Johns Hopkins University School of Medicine. Dr. Levy is board certified in medical oncology and hematology by the American Board of Internal Medicine. He practices out of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital. 

2020 CBPD LEVY - Stage IV NSCLC ALK Positive 74 YO Male with Brain Metastasis
2020 Case Based Panel Discussion presented by Stephen Liu - 74 year old male with stage lV alk positive NSCLC with brain metastasis, and review of the outcomes of genomic profiling: FISH testing vs NGS
Author
Benjamin Levy, MD, Faculty
Image
For this series of case based panel discussions, Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for specific cases in Lung Cancer.

Dr. Levy is Associate Professor of Oncology and Clinical Director of Medical Oncology and Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, and sits on the board of GRACE. Dr. Liu is Associate Professor of Medicine and Director of Thoracic Oncology and Director of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Dr. Julie Brahmer is Director of the Thoracic Oncology Program and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

For this series, the doctors review cases related to non small cell lung cancer.

In this video, the case discussion is regarding a 74 year old male with stage lV alk positive non small cell lung cancer with brain metastasis. The panel also reviews the outcomes of genomic profiling: FISH testing vs NGS.

 

We thank AstraZeneca Merck Genentech Takeda and Lilly for their support!

 

To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.  
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on
Thank you for sharing
By LeviDrake on
Hi bluesun,I don't know of…
By JanineT GRACE … on